Spot on Doc, a very sticky product that already has credibility to become the gold standard in the biosample space. Only a matter of time until FOMO kicks in when a few more big companies incorporate BCT into their products and then others will get dragged along in the slipstream.
The market is very slow catching on to the potential here, perhaps because it is not an OS company. Would be good to see more support for a great Aussie company, would hat to loose it.
Ann: Open Briefing, page-8
-
- There are more pages in this discussion • 23 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BCT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $4.737M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
| BCT (ASX) Chart |
Day chart unavailable
